SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION																	
						Washington, D.C. 20549									OMB APPROVAL		
Check this Section 16.	NT (	NT OF CHANGES IN BENEFICIAL OWNERSHIP								OMB Number: 3235-0287 Estimated average burden							
Instruction :	may continue. 1(b).	366		File		l pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								hours p	per resp	onse:	0.5
1. Name and Address of Reporting Person <sup>*</sup> Riebman Jerome						2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>AZIYO BIOLOGICS, INC.</u> [ AYZO ]							ationship of k all applical Director Officer (g	ble)	Perso	10% Owr Other (sp	ner
(Last) (First) (Middle) C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370						3. Date of Earliest Transaction (Month/Day/Year) 03/08/2021							Delow)	F MEDICAL OF		below) OFFICER	,
(Street) SILVER SPRING, MD 20904 (City) (State) (Zip)					4. lf .	4. If Amendment, Date of Original Filed (Month/Day/Year)							dividual or Joint/Group Filing (Check Applicable ) & Form filed by One Reporting Person Form filed by More than One Reporting Person				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) Date (Month/I					action 2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transaction Code (Instr. 8) 4. Securities Ac Disposed Of (D				5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code V	Amount	ount (A) or Pr (D) Pr		Transaction(s) (Instr. 3 and 4)				iisu. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transa Code ( 8)	ction	5. Number on of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Co		v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	mber				
STOCK OPTION (RIGHT TO BUY)	\$14.53	03/08/2021			A		18,750		(1)	03/08/2031	CLASS A COMMON STOCK	18,750	\$0.00	18,75	0	D	
RESTRICTED STOCK UNITS	(2)	03/08/2021			A		3,125		(3)	(3)	CLASS A COMMON STOCK	3,125	\$0.00	3,125	5	D	

Explanation of Responses:

1. This option vests as to 25% of the shares on March 8, 2022, and in 12 equal quarterly installments thereafter, such that the option shall be fully vested and exercisable on March 8, 2025.

2. Each restricted stock unit represents a contingent right to receive one share of Issuer Class A common stock.

3. The restricted stock units vest in 4 substantially equal annual installments beginning on March 8, 2022 and have no expiration date.

<u>/s/ Ronald Lloyd, Attorney-in-</u> <u>fact for Jerome Riebman</u> 03/10/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.